Dipivefrin

Glaucoma is the second leading cause of irreversible blindness worldwide, and persistently elevated intraocular pressure is the core inducing factor of optic nerve injury. Dipivefrin is a prodrug of adrenergic agonist with no pharmacological activity itself. After entering the eye, it is hydrolyzed by corneal esterase and converted into epinephrine. By agonizing α and β receptors, it exerts the dual effects of reducing aqueous humor production and promoting aqueous humor outflow simultaneously, which can lower intraocular pressure by 20%-27%. It is mainly used clinically for the treatment of primary open-angle glaucoma and ocular hypertension, especially suitable for patients intolerant to epinephrine, and can also be used as a medication for intraocular pressure control after iridectomy for angle-closure glaucoma.Publicly verifiable market data of dipivefrin is temporarily unavailable.The original research developer of dipivefrin is Novartis Pharma, with the original brand name Propine®. It was first approved for marketing by the FDA in 1982. Its core compound patent in the United States expired in 1999, and currently all major patents worldwide have passed the protection period. The original marketed dosage form is 0.1% dipivefrin hydrochloride eye drops, with conventional specifications of 5ml:5mg and 10ml:10mg, which have been included in the FDA Reference Listed Drug Catalog. There are no approved dipivefrin preparation products marketed in China for the time being, and no valid API registration number within the validity period has been found on the CDE API registration platform. (Data as of June 2025, please refer to the official CDE website for the latest information)CATO can provide a full series of dipivefrin impurity reference standards. Most products are in sufficient stock. For in-stock orders paid before 16:00, the goods can be shipped on the same day. The products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the reference standard needs in the stages of API R&D, quality research and registration application.

公开可核实的地匹福林市场数据暂缺。

地匹福林原研企业为诺华制药，原研商品名为Propine®，最早于1982年获FDA批准上市。其美国核心化合物专利已于1999年到期，目前全球范围内主要专利均已过保护期。原研上市剂型为0.1%盐酸地匹福林滴眼液，常规规格为5ml:5mg、10ml:10mg，已被列入FDA参比制剂目录。国内暂无已获批上市的地匹福林制剂品种，CDE原料药登记平台暂未查询到有效在有效期内的API登记号。（数据截至2025年6月，最新请以CDE官网为准）

CATO/佳途科技可提供地匹福林全系列杂质标准品，多数产品备有充足库存，现货订单16:00前付款即可当日发出，产品符合中国药典、FDA等多法规体系要求，能够充分满足原料药研发、质量研究及申报阶段的对照品需求。